Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol 300 micrograms once daily versus placebo with open-label salmeterol control in moderate to severe COPD
2007-005468-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 after 14 days of treatment. Started Jan 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-005468-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005468-28.